Izumo W, Kawaida H, Saito R, Nakata Y, Amemiya H, Maruyama S
World J Surg Oncol. 2025; 23(1):79.
PMID: 40055716
PMC: 11889744.
DOI: 10.1186/s12957-025-03734-0.
Patte C, Pommier R, Ferrari A, Chung F, Ouzounova M, Moulle P
Nat Commun. 2025; 16(1):2197.
PMID: 40038310
PMC: 11880452.
DOI: 10.1038/s41467-025-57305-8.
Melhorn P, Spitzer J, Adel T, Wolff L, Mazal P, Raderer M
J Cancer Res Clin Oncol. 2025; 151(2):86.
PMID: 39971811
PMC: 11839849.
DOI: 10.1007/s00432-025-06126-9.
Chouchane A, Brautigam K, Perren A
Pathologie (Heidelb). 2025; 46(2):127-136.
PMID: 39969551
PMC: 11861404.
DOI: 10.1007/s00292-025-01415-z.
Lamberti G, Campana D
Nat Rev Dis Primers. 2025; 11(1):7.
PMID: 39848965
DOI: 10.1038/s41572-024-00591-1.
Critical considerations for the management of gastrointestinal mixed neuroendocrine non-neuroendocrine neoplasms and pure neuroendocrine carcinomas.
Pavlidis E, Galanis I, Pavlidis T
World J Gastrointest Oncol. 2024; 16(12):4559-4564.
PMID: 39678788
PMC: 11577359.
DOI: 10.4251/wjgo.v16.i12.4559.
Progression of Low-Grade Neuroendocrine Tumors (NET) to High-Grade Neoplasms Harboring the NEC-Like Co-alteration of RB1 and TP53.
Joseph N, Umetsu S, Kim G, Terry M, Perry A, Bergsland E
Endocr Pathol. 2024; 35(4):325-337.
PMID: 39556303
PMC: 11659342.
DOI: 10.1007/s12022-024-09835-y.
Diagnostic and prognostic biomarkers for pancreatic neuroendocrine neoplasms.
Sonnen A, Verschuur A, Brosens L
Pathologie (Heidelb). 2024; 45(Suppl 1):74-82.
PMID: 39556246
DOI: 10.1007/s00292-024-01393-8.
Chromosomal Abnormalities as a Predisposition to Secondary Neurolymphomatosis in Patients with Diffuse Large B-Cell Lymphoma: A Report of Two Cases and a Literature Review.
Watanabe N, Harada S, Sato S, Fukuda Y, Tanaka Y, Yanashima K
Case Rep Oncol. 2024; 17(1):1201-1207.
PMID: 39474529
PMC: 11521521.
DOI: 10.1159/000541552.
Liver metastases in high-grade neuroendocrine neoplasms: A comparative study of hepatic tumor volume and biochemical findings in NET G3 versus NEC.
Melhorn P, Raderer M, Mazal P, Berchtold L, Beer L, Kiesewetter B
J Neuroendocrinol. 2024; 36(12):e13454.
PMID: 39402903
PMC: 11646661.
DOI: 10.1111/jne.13454.
Neuroendocrine transdifferentiation in human cancer: molecular mechanisms and therapeutic targets.
Jiang J, Han D, Wang J, Wen W, Zhang R, Qin W
MedComm (2020). 2024; 5(10):e761.
PMID: 39372390
PMC: 11450264.
DOI: 10.1002/mco2.761.
Prognostic significance of tertiary lymphoid structures in gastric neuroendocrine carcinoma with association to delta-like ligand 3 and neuroendocrine expressions.
Ahn B, Kim D, Kim M, Jeong S, Song I, Kim J
Gastric Cancer. 2024; 28(1):27-40.
PMID: 39352632
DOI: 10.1007/s10120-024-01557-8.
Well-differentiated G1 and G2 pancreatic neuroendocrine tumors: a meta-analysis of published expanded DNA sequencing data.
Andersen K, Detlefsen S, Brusgaard K, Christesen H
Front Endocrinol (Lausanne). 2024; 15:1351624.
PMID: 38868744
PMC: 11167081.
DOI: 10.3389/fendo.2024.1351624.
A case of pancreatic ductal adenocarcinoma with enteroblastic, neuroendocrine, and squamous differentiation with p53 overexpression and loss of Rb expression.
Kodama T, Tani A, Yamane H, Itoh T
Int J Surg Case Rep. 2024; 120:109854.
PMID: 38851063
PMC: 11215098.
DOI: 10.1016/j.ijscr.2024.109854.
Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms.
Angerilli V, Sabella G, Simbolo M, Lagano V, Centonze G, Gentili M
Br J Cancer. 2024; 131(1):159-170.
PMID: 38729995
PMC: 11231306.
DOI: 10.1038/s41416-024-02705-8.
Contemporary Approaches to the Surgical Management of Pancreatic Neuroendocrine Tumors.
Kartik A, Armstrong V, Stucky C, Wasif N, Fong Z
Cancers (Basel). 2024; 16(8).
PMID: 38672582
PMC: 11048062.
DOI: 10.3390/cancers16081501.
Gastric neuroendocrine neoplasms.
Lamberti G, Panzuto F, Pavel M, OToole D, Ambrosini V, Falconi M
Nat Rev Dis Primers. 2024; 10(1):25.
PMID: 38605021
DOI: 10.1038/s41572-024-00508-y.
Molecular Classification of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms: Are We Ready for That?.
Uccella S
Endocr Pathol. 2024; 35(2):91-106.
PMID: 38470548
PMC: 11176254.
DOI: 10.1007/s12022-024-09807-2.
Molecular features of gastroenteropancreatic neuroendocrine carcinoma: A comparative analysis with lung neuroendocrine carcinoma and digestive adenocarcinomas.
Zhang J, Chen H, Zhang J, Wang S, Guan Y, Gu W
Chin J Cancer Res. 2024; 36(1):90-102.
PMID: 38455367
PMC: 10915635.
DOI: 10.21147/j.issn.1000-9604.2024.01.09.
Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns.
Jiang Y, Dong Y, Zhao S, Liu D, Zhang J, Xu X
Cell Commun Signal. 2024; 22(1):164.
PMID: 38448900
PMC: 10916270.
DOI: 10.1186/s12964-024-01545-6.